Treatment of relapsed and refractory acute myelogenous leukemia.
about
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeAllogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeRelapsed acute myeloid leukemia: why is there no standard of care?Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission.Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.Therapeutic options for acute myelogenous leukemia.Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experiencePhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasBiology and management of relapsed acute myeloid leukaemia.Cloretazine for the treatment of acute myeloid leukemia.MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6)Salvage therapy for relapsed or refractory acute myeloid leukemiaA phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Temozolomide and cisplatin in relapsed/refractory acute leukemia.Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.Laromustine (cloretazine).Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations.Effects of PPARγ Ligands on Leukemia.Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient miceAllogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaNew treatments and strategies in acute myeloid leukemia.
P2860
Q27024786-534D4327-E000-4ADF-979C-AFBE83A308EDQ30399209-1E3E347B-1760-40CC-95E6-D1B722C08AF4Q33392185-AC33277D-87D2-441D-8B2B-10B5E82E5AE6Q33769335-E96C24BB-2FCF-44F2-BB63-01112A9D4B14Q33877202-B7C2659E-488B-4556-9CA0-9F3C60B492FFQ34185528-470B50BD-FEBA-4219-93EE-30A40DB653E0Q34316852-F4296C79-92BC-464C-A44C-4C6F86903DE8Q34358512-7E98B1D6-E58E-42AD-841E-66D4A3B60939Q34380840-C646D3E1-587C-4534-B523-F1997F5DBA66Q34772229-42553555-7946-40F7-8A8B-B506D98D71E9Q34983843-208E0431-8C2A-4A96-870E-B5A52DAD9BFEQ35077929-3E751CC6-9B98-4D87-A905-A4A0702FC2B6Q35214520-CBE03F6C-705E-4262-ABE2-44829C08508DQ36075766-BBF494D8-78EA-40FE-867A-2B817297857FQ36085026-54A3735A-52B3-4EF4-AE7A-86F65AE56C2BQ36407434-E1526C13-DEBB-4C1B-8392-4BFC159ABA72Q36511384-41748C4D-D8BF-4708-96E4-D6E6C88D7022Q36571416-69989F91-CD0B-4DF0-9ECC-0F446B4F311CQ36612564-6415510A-6080-4FCE-8B79-7BEB3603EA89Q36682845-8190704C-A83A-4A97-8E69-7188CE64583BQ36832124-DC9D04E4-166F-43E1-B9F1-3CDC58C68A03Q37223615-A50FC11C-B9B6-497C-A9E0-65B64AC4DC7BQ37383528-8817E3D1-81A8-415B-9E05-E2CD52728EACQ37462852-5A144DC6-93DA-44D7-AACF-C01819CB9057Q37693943-DEFEE663-39AC-4FDB-AB76-805CEE1B1343Q37842488-087065FD-2BDB-44FE-933E-5141360DCA30Q38017661-309F7E95-F80E-411D-9E35-78D082C4B1E2Q38042705-3384BAF2-9778-429D-BE78-925A5371F377Q38909191-FB867F53-C937-4807-B7EE-5EC96CE4E280Q38968878-EC7B85D1-2E17-4B1C-8240-3B3A29F8419FQ39002077-11A4384F-465C-4CF0-BE26-A6B06520EFA9Q39067366-0728DB37-CC8A-43F7-9F7B-1B511CF87342Q39240258-FA0E7984-EDFF-482B-B60A-8DEE83CC5BC1Q40569180-271FC422-5193-4B54-A0AE-89C30EA5BAD7Q40614153-11E544B2-FFF2-4424-8D03-8239D74802AFQ40725017-C3A27661-5511-49B5-B887-9BF7169313F5Q40777838-171B9CB3-9C56-423F-B143-AEEAC12664ABQ40780156-C0EB532F-9193-425B-A649-6BFCE4A4388CQ41044948-B057ABD0-478C-426A-BBDF-8641C0EB32C2Q41881090-A00F000F-34DD-4088-9553-BE1B04C3B61D
P2860
Treatment of relapsed and refractory acute myelogenous leukemia.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Treatment of relapsed and refractory acute myelogenous leukemia.
@ast
Treatment of relapsed and refractory acute myelogenous leukemia.
@en
type
label
Treatment of relapsed and refractory acute myelogenous leukemia.
@ast
Treatment of relapsed and refractory acute myelogenous leukemia.
@en
prefLabel
Treatment of relapsed and refractory acute myelogenous leukemia.
@ast
Treatment of relapsed and refractory acute myelogenous leukemia.
@en
P356
P1433
P1476
Treatment of relapsed and refractory acute myelogenous leukemia.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2401568
P577
2000-03-01T00:00:00Z
P6179
1036106851